Global Blood Therapeutics, Inc.

Greetings and welcome to Global Blood Therapeutics Conference Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the prepared remarks. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn this conference over to Mr. Stephen Emmergut. Please go ahead, sir. You may begin.

Thank you, and welcome to GBT's conference call to discuss the company's financial results for the fourth quarter and full year 2020, and to provide a business update. I'm Stephen Immigrant, Head of Communications and Investor Relations. Joining me on the call are Dr. Ted Love, our President and CEO, who will provide a high-level update on our progress in the fourth quarter and over the full year 2020, Jeff Farrow, our Chief Financial Officer, who will provide an overview of our financial results, and David Johnson, or DJ, our Chief Commercial Officer, who will give an update on the OxBrighto launch. Ted will then close with an update on our pipeline activities and other long-term growth initiatives. Earlier this afternoon, we issued a press release announcing GBT's progress in financial results for the fourth quarter and year-ended December 31st, 2020. Before we begin, I would like to remind you that certain statements we make on this call that are not historical facts may be forward-looking statements that are subject to risks and uncertainties. Information concerning factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements are contained in our SEC filings, including but not limited to our most recent annual report on Form 10-K, as well as in today's press release. from the investors page of our company website at gvt.com. The forward-looking statements made on this call are only as of the time they are made and should not place undue reliance on such statements. Future events or simply the passage of time may cause our beliefs to change, and we disclaim any obligation to update any forward-looking statements other than as required by law. With that, I will turn the call over to Ted.

Thank you, Stephen, and good afternoon, everyone. 2020 was a historic year for GBT, headlined by the launch of Oxprida and significant progress on our R&D pipeline. We are in a position of strength, and we continue to build value with multiple commercial, regulatory, and clinical milestones in the coming months and years. It is clear that Oxprida's fundamentals are strong. This is supported by several facts. First, strong adoption and awareness. During the first full year of the launch, we generated nearly 124 million in revenue, making it the most successful launch in sickle cell disease history. This happened despite a once-in-a-century pandemic. In addition, physician and patient awareness of OxyPrata is extremely high. Nearly 100% of healthcare professionals who are aware of OxyPrata either have prescribed it or plan to. Second, robust data. The growing body of clinical data, including the HOPE study, shows that OXFRADA resulted in durable improvement in hemoglobin and hemolysis over 72 weeks of treatment. Both the HOPE study and the published real-world experience data shows most patients taking OXFRADA report improvement in overall health status. We've seen, in real-world data, statistically significant reductions in blood transfusions and VOCs. And I know many patients that have returned to their normal daily activities, including getting back into the workforce. And third, broad access. Our analysis of prescription trends confirmed that HCPs are starting a broad range of patients on Oxprida, irrespective of their baseline hemoglobin, VOC history, and age. We established broad payer coverage in less than a year, one quarter ahead of our 2020 goal, which demonstrates that payers understand the benefits of Oxprida. Based on these points, we believe Oxprida is well on its way to become foundational in SCD care. In every launch, you learn and adapt. COVID-19 has accelerated this process for our team, and we believe this will put GBT in an even stronger position coming out of the pandemic. Until that time comes, we believe we can continue to sustain our current levels of new prescriptions and look forward to the opportunity to accelerate our growth when the pandemic subsides. We have a deep appreciation for the disproportionate impact of COVID-19 on sickle cell patients and the racial inequalities in healthcare, which have been magnified by the pandemic. As part of our long-term commitment, GBT support for the sickle cell community has increased each year, and we are proud to have helped this community in a variety of ways in 2020. Total financial support was more than $2 million, and a couple of specific examples include, number one, GBT, our employees, and members of our board contributed nearly $400,000 to directly support the urgent patient and family needs related to the COVID-19 pandemic. Number two, we also provided funding to nonprofit organizations working to improve access to care in SED through our ongoing Excel grant program. And thirdly, we hosted the ninth annual Sickle Cell Disease Therapeutics Conference to further advance healthcare for people living with sickle cell disease. Overall, we are very happy with our launch progress. GBT is a clear leader in sickle cell disease, and we are poised to deliver for patients in 2021 and beyond. With that, I will turn the call over to Jeff to provide an update on our fourth quarter and full year results.